Indivior Pharmaceuticals Inc. Common Stock (INDV)
Stock · NASDAQ · Health Care
$32.41as of 10/16/2026
Price chart
Active signals
INDV Signal Track Record
How signals performed across all stocks →What INDV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +1.3% | 55% | September 17, 2026 |
| Bollinger Band Breakout | 22 | +4.2% | 59% | September 22, 2026 |
| Bollinger Band BreakdownActive now | 20 | -4.8% | 45% | August 3, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -2.0% | 43% | October 8, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INDV
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 827
- Website
- www.indivior.com/
Fundamentals
- 1-day range
- $33.54$34.86
- Market cap
- $4.82B
- P/E (trailing)
- 11.25
- P/E (forward)
- 6.88
- EPS (trailing)
- $2.78
- Dividend yield
- —
- Beta
- 0.49
- Avg. volume
- 2.25M
- Ex-dividend date
- October 30, 2026
- Dividend pay date
- November 6, 2026
How Indivior Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Indivior Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INDVIndivior Pharmaceuticals Inc. Common Stock$32.45▼ 3.48%Market cap $4.82BP/E 11.25$23.67$42.81
- DYNDyne Therapeutics Inc. Common Stock$14.25▼ 6.80%Market cap $4.83BP/E —$13.88$27.31
- EWTXEdgewise Therapeutics Inc. Common Stock$37.19▼ 2.64%Market cap $4.78BP/E —$14.25$48.51
- ACADACADIA Pharmaceuticals Inc. Common Stock$19.12▼ 2.99%Market cap $4.87BP/E 8.79$18.39$30.96
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- GRFSGrifols S.A. American Depositary Shares$7.64▲ 1.33%Market cap $5.38BP/E 12.88$8.43$12.15
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INDV Indivior Pharmaceuticals Inc. Common Stock | $4.82B | 11.25 | $32.45 | ▼ 3.48% | $23.67$42.81 |
| DYN Dyne Therapeutics Inc. Common Stock | $4.83B | — | $14.25 | ▼ 6.80% | $13.88$27.31 |
| EWTX Edgewise Therapeutics Inc. Common Stock | $4.78B | — | $37.19 | ▼ 2.64% | $14.25$48.51 |
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.87B | 8.79 | $19.12 | ▼ 2.99% | $18.39$30.96 |
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| GRFS Grifols S.A. American Depositary Shares | $5.38B | 12.88 | $7.64 | ▲ 1.33% | $8.43$12.15 |
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Indivior Pharmaceuticals, Inc. Declares Special Cash DividendYahoo · 9/17/2026
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo · 9/14/2026
Insider Activity
Insider Actions →- Woodrow D. Anderson · August 27, 2026 · Buy1.5K @ $35.69
- Mark Stejbach · August 10, 2026 · ?36.0K @ $1.62
- Woodrow D. Anderson · August 5, 2026 · Buy1.5K @ $36.28
- Christian Heidbreder · July 10, 2026 · Sale18.6K @ $41.14
- Joseph Ciaffoni · June 22, 2026 · Option Exercise1.27M
- Joseph Ciaffoni · June 22, 2026 · Tax Withholding612.5K @ $38.32
- Christian Heidbreder · June 11, 2026 · Sale18.6K @ $38.06
- Timothy Thompson · June 11, 2026 · ?3.9K @ $13.88
- Timothy Thompson · June 11, 2026 · ?1.9K @ $13.88
- Juliet Thompson · June 11, 2026 · ?1.9K @ $13.88
- Ryan Preblick · June 8, 2026 · Sale36.0K @ $37.7
- Shaun Thaxter · May 14, 2026 · ?100.0K @ $0.446414
- Tatjana May · May 14, 2026 · ?22.3K @ $0.445785
- David E. Wheadon · May 13, 2026 · Grant10.4K
- Stuart A. Kingsley · May 13, 2026 · Grant6.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 118.33M
- Total value held
- $3.50B
- Institutional holders
- 283
- Unknown18.54M
- Unknown6.98M
- Unknown5.59M
- Unknown4.90M
- Unknown4.75M
- Unknown4.60M
- Unknown4.53M
- Unknown4.32M
- Unknown3.71M
- Unknown3.51M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Indivior reports Sublocade sales growth and higher profitability
Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.
Indivior reports Sublocade sales growth and higher profitability. Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.